MeiraGTx reports Q3 EPS (74c), consensus (55c)

Reports Q3 revenue $5.103M vs $4.816M last year. “We are very happy to now have Sanofi as one of our top shareholders,” said Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx. “Sanofi’s interest in large market indications validates what MeiraGTx has been pioneering since inception of the Company – the use of genetic medicines and gene regulation to address large chronic diseases, not just rare inherited disorders. With our end-to-end manufacturing infrastructure and novel platform technologies, we are confident we can use our genetic medicines toolkit to treat much larger populations of patients without prohibitively high costs.”